Results 141 to 150 of about 8,893 (235)

Weight loss mediates improvement in proinsulin processing during GLP-1 receptor agonist treatment

Diabetology & Metabolic Syndrome
Aims To observe the effect of glucagon-like peptide-1 receptor agonists (GLP-1RA) combined with metformin and metformin monotherapy on proinsulin changes in patients with obesity following weight loss.
Renjiao Liu, Dangmin Hou, Mingxin Leng, Zhouhuiling Li, Yifang Zhang, Lingling Liu, Xincheng Wang, Chunjun Li   +7 more
doaj   +1 more source

GLP-1 receptor agonist increase retained gastric contents on EGD and same-day colonoscopy reduces this risk

Frontiers in Medicine
IntroductionWith the rise in glucagon-like peptide 1 receptor agonist (GLP-1RA) medication usage for Type 2 diabetes mellitus and weight loss, concerns have been raised regarding safety and primary aspiration risk when undergoing anesthesia procedures ...
Dirin Ukwade, Luis J. Hernandez, Zeel Modi, Hasan S. Raza, Michael Siegel, Dexter Nwachukwu, Paya Sarraf, Abdullah Memon, Marya Booth, Karen Cooper, Brian R. Boulay, Ece A. Mutlu   +11 more
doaj   +1 more source

A phase 1 single and multiple ascending dose study of orforglipron in Japanese participants with type 2 diabetes

Journal of Diabetes Investigation, Volume 17, Issue 2, Page 205-213, February 2026.
Orforglipron, a novel oral non‐peptide GLP‐1 receptor agonist, was evaluated in a Phase 1, double‐blind, placebo‐controlled, randomized, single and multiple ascending dose study in Japanese participants with type 2 diabetes. The safety and tolerability profile of orforglipron was consistent with those of other GLP‐1 receptor agonists, and ...
Kenji Ohwaki, Chino Nakamura, Risa Nasu, Kazumasa Takenouchi, Tetsuaki Hirase   +4 more
wiley   +1 more source

Incidence of treatment intensification based on HbA1c trends in people with type 2 diabetes

Journal of Diabetes Investigation, Volume 17, Issue 2, Page 321-329, February 2026.
We conducted this study to examine the incidence of treatment intensification in response to changes in the HbA1c levels in people with type 2 diabetes. Of the 5,683 patients, 4,553 (80.1%) did not undergo treatment intensification at the second consultation.
Erika Sugito, Takehiro Sugiyama, Ryotaro Bouchi, Akiyo Tanabe, Kohjiro Ueki, Mitsuru Ohsugi   +5 more
wiley   +1 more source

The biology of PKM2 in the metabolism and senescence in diabetic kidney disease

Journal of Diabetes Investigation, Volume 17, Issue 2, Page 197-204, February 2026.
ABSTRACT Diabetic kidney disease (DKD) is one of the most common causes of chronic kidney disease that leads to end‐stage kidney disease, and its progression is closely linked to metabolic stress within renal tubular cells. Under long‐term hyperglycemia, cells shift their glucose metabolism from normal oxidative phosphorylation toward glycolysis.
Md. Imrul Kayes, Keizo Kanasaki
wiley   +1 more source

IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy [PDF]

, 2015

core   +1 more source

Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients

Diabetes, Metabolic Syndrome and Obesity, 2015
Leigh MacConell,1 Kate Gurney,2 Jaret Malloy,1 Ming Zhou,3 Orville Kolterman4 1Clinical Development, Bristol-Myers Squibb, San Diego, CA, USA; 2Medical Writing, Bristol-Myers Squibb, San Diego, CA, USA; 3Biostatistics, Bristol-Myers Squibb, Princeton, NJ,
MacConell L, Gurney K, Malloy J, Zhou M, Kolterman O   +4 more
doaj  

GLP-1RAs for the treatment of obesity in women after menopause

Maturitas, 2022
Paschou, S.A., Kotsa, K., Peppa, M., Hatziagelaki, E., Psaltopoulou, T.   +4 more
openaire   +3 more sources

Modern Diets, Metabolic Inequity, and Race–Ethnic Disparities: Unraveling the Associations With MASLD and Cancer Risk

Journal of Gastroenterology and Hepatology, Volume 41, Issue 2, Page 573-585, February 2026.
ABSTRACT Metabolic dysfunction–associated steatotic liver disease (MASLD) is quickly emerging as a global public health concern, primarily fueled by the rising consumption of processed and ultraprocessed foods. This global health issue, showing a 50% increase in prevalence over two decades to 38% of the global population, is now the second most common ...
Arunkumar Krishnan, Kunal C. Kadakia, Sean Richard Rudnick, Andrew S. deLemos, James Dewitt Miller, Ted Xiao, Mark W. Russo, Dionisios Vrochides, Andrew Schreiner, Ajay Dharod   +9 more
wiley   +1 more source

Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD [PDF]

Background and Aims Glucagon-like peptide 1 receptor agonist (GLP-1RA) therapies deliver histological benefit in people with metabolic dysfunction-associated steatotic liver disease (MASLD).
Cobbold, Jeremy F, Cornfield, Thomas, Dong, Jiawen, Hodson, Leanne, Moolla, Ahmad, Mouchti, Sofia, Mózes, Ferenc E, Neubauer, Stefan, Othonos, Nantia, Poolman, Toryn, Ray, David W, Smith, Kieran, Thomaides-Brears, Helena, Tomlinson, Jeremy W, White, Sarah   +14 more
core